SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Office of Cancer Survivorship, National Cancer Institute. About cancer survivorship research: survivorship definitions. Bethesda, MD: National Cancer Institute; 2010. http://www.cancercontrol.cancer.gov/ocs/definitions.html. Accessed June 15, 2010.
  • 2
    Office of Cancer Survivorship, National Cancer Institute. Estimated US cancer prevalence counts: who are our cancer survivors in the US?. Bethesda, MD: National Cancer Institute; 2010. http://www.cancercontrol.cancer.gov/ocs/prevalence/index.html. Accessed June 15, 2010.
  • 3
    Hewitt M, Greenfield S, Stoval E, eds. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academy Press; 2005.
  • 4
    Adler NE, Page AEK, eds. Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs. Washington, DC: National Academy Press; 2008.
  • 5
    Rowland J. Cancer survivorship—United States, 1971-2001. MMWR Weekly. 2004; 53: 526-529.
  • 6
    Ganz PA. Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst Monogr. 2001; 30: 130-134.
  • 7
    Litwin MS. Quality of life following definitive therapy for localized prostate cancer: potential impact of multiple therapies. Curr Opin Urol. 2003; 13: 153-156.
  • 8
    Hewitt M, Herdman R, Holland J, eds. Meeting Psychosocial Needs of Women with Breast Cancer (report of the National Cancer Policy Board/Institute of Medicine and National Research Council). Washington, DC: National Academy Press; 2004.
  • 9
    Kornblith AB. Psychosocial adaptation of cancer survivors. In: Holland JC, ed. Psycho-Oncology. New York: Oxford University Press, 1998: 223-241.
  • 10
    Yabroff KR, Warren JL, Banthin J, et al. Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care. 2009; 47( suppl): S64-S69.
  • 11
    Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002; 40( suppl): 104-117.
  • 12
    Tangka FK, Torgdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States, Cancer. 2010; 116: 3477-3484.
  • 13
    Thorpe KE, Howard D. Health insurance and spending among cancer patients. Health Aff. 2003; W3: 189-198.
  • 14
    Soni A. The Five Most Costly Conditions 2000 and 2004: National Estimates for the Civilian Non-Institutionalized Population. MEPS Statistical Brief No. 167. Rockville MD: Agency for Healthcare Research and Quality; 2007.
  • 15
    Howard DH, Molinari NA, Thorpe KE. National estimates of medical costs incurred by nonelderly cancer patients. Cancer. 2004; 100: 883-891.
  • 16
    Ezzati-Rice TM, Rohde F, Greenblatt J. Sample Design of the Medical Expenditure Panel Survey Household Component, 1998-2007. Methodology Report No. 22. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
  • 17
    American Cancer Society. Cancer Facts and Figures 2007. Atlanta, GA: American Cancer Society; 2007.
  • 18
    Office of the Actuary, Centers for Medicare and Medicaid Services. National Health Expenditures Accounts: Definitions, Sources, and Methods, 2008. Baltimore, MD: Centers for Medicare and Medicaid Services; 2008.
  • 19
    Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70: 41-55.
  • 20
    Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. Version 3.0.0. Statistical software components series. Chestnut Hill, MA: Department of Economics, Boston College; 2003. http://www.ideas.repec.org/c/boc/bocode/s432001.html. Accessed December 6, 2010.
  • 21
    Angrist JD. Estimation of limited dependent variable models with dummy endogenous regressors: simple strategies for empirical practice. J Business Econ Stat. 2001; 19: 2-16.
  • 22
    Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009; 101: 1044-1048.
  • 23
    Johnson A. Cancer drugs' cost-effectiveness questioned. Wall Street Journal. July 2, 2009. http://www.online.wsj.com/article/SB10001424052970203872404574258302761872972.html. Accessed June 15, 2010.
  • 24
    Szabo L. Prices soar for cancer drugs. USA Today. July 10, 2006. http://www.usatoday.com/news/health/2006-07-10-cancer-costs_x.htm. Accessed June 15, 2010.